



## HA<sup>nano</sup> Surface® Part of Novel Orthopaedic Oncology 510(k) Clearance

**Promimic licensee, Onkos Surgical, receives FDA clearance of new addition to Limb Salvage System, marking the entry of HA<sup>nano</sup> Surface® into the large joint implant market with a system that may improve healing for orthopaedic oncology patients.**

*GOTHENBURG, July 7, 2021* – Promimic AB, the world’s leading innovator in nanometer thin surface treatments for improved osseointegration, is pleased to share the recent FDA 510(k) clearance of Onkos Surgical’s BioGrip® Modular Porous Collars, treated with HA<sup>nano</sup> Surface technology, a revolutionary solution that is intended to address the clinical challenges of implant loosening in orthopaedic oncology and complex revision surgery.

Promimic’s HA<sup>nano</sup> Surface is a market-leading technology designed to improve osseointegration.

“Clinical use of HA<sup>nano</sup> Surface is ever-expanding and with this latest clearance, we enter a new market segment of large joint implants. This was an exceptional accomplishment as the Onkos ELEOS™ Limb Salvage System supports some of the most complicated cases in oncology patients and those that need complex revision surgery. We are honored to have worked alongside the Onkos Surgical team to prepare this product for launch,” says Magnus Larsson, CEO, Promimic AB.

Onkos Surgical is a leading innovator of solutions for musculoskeletal oncology and complex orthopaedic procedures. Its modular collar portfolio features the new BioGrip® 3D-printed implant technology treated with HA<sup>nano</sup> Surface.

“It is well documented in the literature that implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. These patients deserve better, and our latest ELEOS™ Limb Salvage innovation, with a unique porous structure and the novel, uniform HA treatment surface from Promimic has the potential to help surgeons and patients with these challenges. The collaboration with Promimic has been fantastic throughout the entire development process,” said Sean Curry, SVP of Commercial Operations, Onkos Surgical.

### **About Promimic**

Promimic has developed a state-of-the-art nanotechnology that mimics nature, making it possible to create a unique bioactive surface on any implant. HA<sup>nano</sup> Surface has demonstrated faster and stronger osseointegration in over 30 *in vivo* and *in vitro* studies, with over 400,000 clinical implantations to date. Promimic operates primarily in the United States, Europe, and South America, with offices in Gothenburg, Sweden and Austin, Texas. Current applications include products in the cardiothoracic, dental, spine and total joint markets.

### **Contact:**

Magnus Larsson, CEO, +46 (0)709-776 477, [magnus.larsson@promimic.com](mailto:magnus.larsson@promimic.com)

More information: [www.promimic.com](http://www.promimic.com)

### **About Onkos Surgical**

Onkos Surgical is a leader in innovative solutions for musculoskeletal oncology and complex orthopaedic procedures. With its Precision Orthopaedics approach, surgeons are better informed about patient-specific clinical challenges and are able to plan and implement a more precise reconstruction. This personalized approach supports improved patient outcomes and experiences using the latest innovations in virtual surgical planning, 3D modeling and printing, implant design, and workflow optimization. More than 350 of the leading academic medical institutions in the US choose Onkos Surgical for Precision Orthopaedics.

More information: [www.onkossurgical.com](http://www.onkossurgical.com)

### **Forward Looking Statements**

Certain statements made in this release that are not statements of historical or current facts are forward-looking statements which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the companies to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “future,” “believes,” “expects,” “may,” “will,” “should,” “potential,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations but are subject to known and unknown risks and uncertainties including, without limitation, distribution challenges, market trends and demand, product efficacy and safety concerns, product or raw material availability and other supply constraints. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results. The forward-looking statements included are made only as the date of this release. The companies assume no obligation to update any information or forward-looking statement contained herein, save for any information required to be disclosed by law.